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ORIGINAL STUDIES

Initial in-human experience with the conveyor cardiovascular
system for the delivery of large profile transcatheter
valve devices
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Abstract
Objectives: To determine the safety and efficacy of the conveyor cardiovascular
system (CCS) to facilitate the delivery of large profile transcatheter valve devices.

Department of Surgery, UNC Chapel, Chapel
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Background: Transcatheter valve devices rely on force provided by the operator to
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be delivered to their intended position. This delivery may be challenging in a variety
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of anatomic scenarios. The ability to provide steering from the tip of the device by
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forming an arterial venous loop may help overcome these challenges.
Methods: Between May, 2019 and October, 2020, five patients were recruited for
delivery of transcatheter valve devices with the CCS. These patients were deemed
by the operators to have challenging anatomy which could make conventional valve
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delivery difficult or impossible. These patients were recruited as part of an FDA

[Correction added on 17 October 2021, after
first online publication: Edits have been made
to this version. None of the edits affect the
meaning of the content.]

SAPIEN-3 valve. One patient each underwent transcatheter aortic valve (TAVR)

approved early feasibility study or through an institutional review board approved
compassionate use protocol.
Results: Three patients underwent transcatheter mitral valve replacement with a
implantation with a SAPIEN 3 and 1 patient underwent TAVR implantation with a
Lotus valve. All patients underwent successful implantation of the valve and removal
of the CCS and valve delivery systems. There was no more than trivial mitral regurgitation post procedure in any patient and there was no more than trivial paravavular
leak. There were no major in-hospital complications.
Conclusions: The CCS facilitates the delivery of large profile transcatheter valve
devices in challenging anatomic scenarios. Further studies are needed with additional
valve technologies.
KEYWORDS

antegrade, aortic, mitral, TAVR, TMVR, transeptal
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I N T RO DU CT I O N

aortic valve replacement (SAVR) as the most common treatment for
patients with aortic stenosis in the United States.1 Multiple different

The advent of transcatheter technology has forever changed the

devices for both mitral and tricuspid valve replacement are in clinical

landscape of the treatment of structural heart disease. Recently,

trials and it is likely these too may 1 day eclipse the number of surgical

transcatheter aortic valve replacement (TAVR) has supplanted surgical

interventions. A commonality in each of these technologies is the

Catheter Cardiovasc Interv. 2021;1–6.

wileyonlinelibrary.com/journal/ccd

© 2021 Wiley Periodicals LLC.

1

2

O'NEILL ET AL.

reliance on advancing and steering large profile devices from behind

Durham, NC, United States) or through an institutional review board

using guide wires and/or steerable sheaths (retrograde steering) most

approved compassionate use protocol. Each patient underwent informed

commonly from the femoral artery or vein to the targeted valve. In the

consent prior to their procedures. Inclusion criteria were technical fac-

aortic position, several commonly encountered anatomic variances may

tors which in the opinion of the operators would make conventional

make this method of delivery challenging. These would include a hori-

retrograde delivery of transcatheter devices extremely challenging or

zontal aortic arch, aortic aneurysm, and bicuspid valves, particularly

would be associated with higher complications. These scenarios included

those which are heavily calcified with fused raphe, valve in valve or

a horizontal aortic arch and bicuspid valve with bulky calcification in

small annuli. In the mitral position, a thickened interatrial septum, which

the aortic position, and anticipated challenges with septal crossing

is commonly found in post-surgical patients, and inadequate transeptal

or co-axiality within the surgical mitral valve prosthesis in the mitral

height may lead to injury or tearing of the septum. High profile delivery

position. Possible complications could include PVL, the need for perma-

systems may need to navigate an extreme angle to reach the mitral

nent pacemaker implantation, injury to the ascending aorta, and injury

valve annulus within the left atrium. These can also lead to challenges

to the interatrial septum or left ventricle (LV). Patients who met these

in maintaining a co-axial position.

criteria underwent valve implantation with assistance of the CCS.

A potential solution to these challenges is the ability to steer large

The components of the CCS are listed in Figure 1. The system

profile devices from the front (antegrade steering) with the formation

consists of the following three subcomponents: the right-to-left con-

of a specialized, protected atrioventricular (AV) loop. This technique is

duit (RLC) (Figure 1A); the conveyor cable (Figure 1B); and the left

well known in the field of paravalvular leak (PVL) closure, where ser-

ventricular redirector-low profile sheath (LVR-LPS) with dilator

piginous leaks may preclude the retrograde delivery of closure

(Figure 1C). A transeptal puncture is performed in the standard fash-

devices. However, the experience with TAVR has been mixed. The

ion (Figure 2A). A Versacore (Abbott, Abbott Park, IL, United States)

first cases of TAVR relying on antegrade valve delivery resulted in 1/3

guidewire is introduced into the left atrium and a balloon septostomy

of patients requiring CPR during the manipulation across the aortic

is performed with a 12 mm septostomy balloon (Figure 2B). The tran-

valve.2 As a result of this, antegrade delivery has been reserved for

septal sheath is removed and the RLC is advanced into the left atrium

those patients principally with no other peripheral access, eliminating

beyond the mitral valve orifice. The tip of the RLC is then flexed and

the potential advantages of this system in those aforementioned chal-

pulled back, while applying counter clockwise torque, until it crosses

lenging anatomic TAVR cases.3

into the mitral valve. The system is then advanced and curled until the

Much of the hemodynamic instability seen in these cases is due

tip points toward the aorta. The Versacore is advanced into the aorta

to a stiff wire across the aortic and mitral valve resulting in simulta-

followed by the RLC (Figure 2C). The Versacore wire is snared from

neous aortic and mitral insufficiency. Dedicated devices to allow for

the left femoral artery (Figure 2D) and the RLC is removed and

the efficient creation of an AV loop that could provide antegrade

exchanged briefly for the septostomy balloon, as it is advanced

steering without hemodynamic instability are therefore needed to

through the chords to confirm no chordal entrapment of the system.

help overcome the challenges of retrograde steering. We present our

The RLC is then readvanced into the distal aorta over the Versacore

initial experience with the conveyor cardiovascular system (CCS)

wire. The Versacore wire is removed and replaced by the Conveyor

(Conveyor Cardiovascular Ltd, Dublin, Ireland) for delivery of trans-

Cable which is then snared and externalized. At this time the arterial

catheter devices in challenging anatomy.

sheath is removed and the LVR sheath and dilator is locked into the
conveyor cable. The cable is then pulled from the venous side
allowing the LVR to easily track into the descending aorta and lock

2
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METHODS

onto the RLC (Figure 2E). With a push pull method the LVR is then
positioned in the apex of the LV and the RLC is released. The LVR

Patients with aortic or mitral valve disease were recruited as part of

features a high force retracting guy wire (Figure 1C) that provides for

an FDA approved early feasibility study (sponsored by Synecor LLC,

the strong antegrade steerability of the conveyor cable in the LV in

F I G U R E 1 Conveyor cardiovascular system. (A) Right to left catheter (RLC). (B) Conveyor cable. (C) Left ventricular redirector (LVR) [Color
figure can be viewed at wileyonlinelibrary.com]

3
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F I G U R E 2 Procedural steps in creating arterial–venous (AV) loop with the conveyor system. (A) Standard transeptal puncture. (B) Balloon
septostomy to allow catheter passage. (C) Versacore wire is advanced into the ascending aorta. (D) Versacore wire is snared to create AV rail
allowing exchange of right-to-left conduit (RLC). (E) Connection of the RLC and left ventricular redirector (LVR). (F) Pulling on conveyor cable
allows the LVR to pull valve nose cone away from outer curvature of arch to center in the annulus [Color figure can be viewed at
wileyonlinelibrary.com]

TABLE 1

3

Baseline characteristics

|

RE SU LT S

% (N = 5 overall)

From March, 2019 to October, 2020, five patients were recruited.

Age (years)

68.4

STS score

9.0 ± 7.6

Male

20 (1)

NYHA class III or IV

40 (2)

HTN

80 (4)

tion. Table 2 shows the characteristics of valve implantation. Three of

Diabetes

20 (1)

five patients underwent implantation for a degenerated mitral valve

End stage renal disease

20 (1)

prosthesis in previous surgical valves, with two of these patients hav-

Prior cerebrovascular accident

20 (1)

ing previously had more than one mitral valve intervention. The other

COPD

20 (1)

two patients underwent implantation for native aortic valve stenosis.

Prior MI

20 (1)

The rationale for utilization of the CCS in each of these procedures is

Prior CABG

20 (1)

also listed in Table 2. For the mitral valve cases, the device would

Atrial fibrillation

40 (2)

assist in transit across the thickened septum to avoid tearing, and to

Prior permanent pacemaker

40 (2)

Left ventricular ejection fraction (%)

62.6 ± 6.1

Table 1 shows patient baseline characteristics. The majority of
patients who were treated were female. Most patients were not on
dialysis and had a normal left ventricular ejection fraction. Two of five
patients had a previous pacemaker placement and had atrial fibrilla-

help maintain co-axiality within the mitral valve prothesis. For the aortic valve cases the device would allow passage across the calcified
raphe of the bicuspid valve and to keep the valve centered, given the

Abbreviations: CABG, coronary artery bypass grafting; COPD, chronic
obstructive pulmonary disease; DMII, type; MI, myocardial infarction;
NYHA, New York Heart Classification; STS, Society of Thoracic Surgeons.

horizontal nature of the aortic arch. In all patients, the transcatheter
valve was successfully delivered into the intended position and the
CCS and valve delivery system were removed without incident. There
were no major adverse cardiovascular events as per Valve Academic

order to facilitate centering of the large valve prosthesis within the

Research Consortium definitions.4 In the aortic stenosis patients,

intended valve annulus (Figure 2F), Video S1. Additionally, the LVR

there was no need for permanent pacemaker implantation.

while positioned in the left ventricular apex, protects the apex from
trauma or perforation due to the valve delivery systems or cable.

Post echocardiographic variables are shown in Table 3. There was
no more than trivial mitral regurgitation in both the aortic and mitral

4
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TABLE 2

Characteristics of valve implantation

Successful valve
delivery (y/n)

Major VARC
complications in
hospital (y/n)

29 mm
SAPIEN 3

y

n

Transit across
septum and
delivery

23 mm
SAPIEN 3

y

n

Native

Horizontal root and
bicuspid

29 mm
SAPIEN 3

y

n

Aortic

Native

Horizontal root and
bicuspid

27 mm
LOTUS
EDGE

y

n

Mitral

Surgical (MVRx1)

Transit across
septum and
delivery

29 mm
SAPIEN 3

y

n

Patient

Aortic or mitral
valve disease

Native or postsurgical valve disease

Rationale for
conveyor use

1

Mitral

Surgical (MVRx2)

Transit across
septum and
delivery

2

Mitral

Surgical (MV Repair
and TMVR)

3

Aortic

4

5

Valve type

Abbreviations: mm, millimeter; MVR, mitral valve replacement; N, no; TMVR, transcatheter mitral valve replacement; VARC, Valve Academic Research
Consortium; y, yes.

TABLE 3

Echocardiographic procedure results

Post mean
gradient (mmHg)

Post valve
area (cm2)

Mitral
regurgitation
Pre

Mitral
regurgitation
Post

Paravavular
leak

Patient

Baseline mean
gradient (mmHg)

Baseline valve
area (cm2)

1

14.3

n/a

3.8

n/a

None

Trivial

None

2

11.1

n/a

10.3

n/a

None

None

None

3

41.9

0.78

9.8

1.93

Trivial

Trivial

None

4

30.5

0.82

11.6

2.25

Mild

Trivial

None

5

19.3

n/a

9.3

n/a

None

Trivial

None

Abbreviation: n/a = not applicable.

valve patients post valve implantation. Post-procedure mean gradients

vascular complications in a single center study,6 and aortic angulation

were decreased from baseline in both groups of patients. Finally, there

may impact procedural success with self-expanding valves vs. balloon

was no evidence of PVL in any patients.

expanding valves.7 The inability to control the valve by retrograde
steering may be partially overcome through snaring of the valve delivery system prior to deployment, however, this force cannot be applied

4
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to the valve tip.8 The ability to move the valve from the tip with the

DISCUSSION

CCS may allow the valve to be moved off the outer curvature of the
Our series represents the initial experience with the CCS for the deliv-

aorta and to center the valve within the annulus for deployment which

ery of large bore, high profile transcatheter valve devices. Several

may help address some of these challenges (Figure 3).
Heavily calcified bicuspid valves remain a challenging scenario in

important insights emerge from this study.
With respect to aortic stenosis, the delivery of transcatheter valves

TAVR. Accounting for half of younger patients who undergo SAVR,9

in horizontal roots may be assisted by the CCS. TAVR is hampered by

TAVR operators are more commonly encountering patients with

increasing aortic root angulation principally due to challenges of align-

biscuspid aortic valve disease. In a multi-center study of more than

ment within the valve annulus. This may cause the need for multiple

1000 patients with biscuspid AS treated predominantly with a balloon

valve repositionings, recaptures, or deployment of the valve in a non-

expandable valve, 26% had both a calcified raphe and excess leaflet

coaxial fashion leading to paravavular regurgitation.5 Previous studies

calcification. These patients had higher rates of 2-year all-cause mor-

have shown that 30% of patients have an aortic root angle of >50.

tality, aortic root injury, and moderate-to-severe PVL.9 The asymmet-

0

Real world experience with horizontal roots greater than 51 with

ric calcium distribution along with fused raphe may lead to difficulties

self-expanding valves has shown an increased rate of stroke and major

with advancing the valve across the annulus and with optimal

5

O'NEILL ET AL.

F I G U R E 3 Transcatheter aortic valve
(TAVR) deployment in horizontal roots.
(A) Conventional TAVR deployment in a
horizontal root of 78 . The TAVR valve
pressed against the membranous septum.
(B) TAVR deployment in a root of 70
with the conveyor system. Here the valve
is off the membranous septum just before
valve deployment

expansion of the outer valve frame.10 In addition, narrowing of the

stenosis and no other suitable vascular access.3 The advantages of

aortic valve complex above the true annulus can lead to a less circular

this technique include the ability to apply force to both sides of the

deployment,11 which can be more challenging with self-expanding

device in order to navigate the smaller space of the left atrium. The

valves. The AV rail created by the CCS may help maintain the central

continuous loop may prevent unintended movement of the nose cone

position of the valve during deployment to allow for a more uniform

of the delivery system from inadvertent injuries of the delicate por-

distribution of force.

tions of the heart. The unique design of the CCS cable (braided coat-

Conduction disturbances remain a frequently encountered

ing and polymer jacket) coupled with the anterograde steering force

challenge post TAVR and have been associated with a higher

of the LVR prevents interaction with the leaflets of the aortic and

incidence of death or heart failure admission at 1 year.12 Studies

mitral valve leaflets which may lead to hemodynamic instability by

have consistently shown that long framed self-expanding valves are

causing severe mitral and/or aortic regurgitation.

particularly prone to conduction disturbances post TAVR.13,14 This is
partially due to their inability to self-center, causing compression of
the membranous septum during expansion. Calcifications in the

5
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LVOT under the left coronary cusp are thought to lead to higher
rates of pacemaker dependency through a similar mechanism of
valve expansion toward the septum.

15,16

This was a pilot study of a novel system to facilitate percutaneous

Although a higher implanta-

valve delivery. As such, these findings are hypothesis generating and

tion depth may obviate some of this risk, the initial positioning

will need to be confirmed in future studies. In addition, this was a sin-

may still cause trauma.14 The CCS may help avoid this initial injury

gle center study and events were self-adjudicated. There was no cen-

once more through maintaining a centralized position during valve

tral core lab to review echocardiographic results.

delivery and expansion.
Transcatheter mitral valve replacement (TMVR) has shown promise in several early feasibility studies.17,18 Given the size of the

6
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delivery equipment required however, many of these systems require
a transapical approach. A transeptal delivery system is ideal to

The CCS may facilitate transcatheter valve delivery in patients who

avoid the need for a transapical exposure in patients with multiple

were deemed to have challenging structural anatomy. This pilot study

co-morbidities. Transeptal delivery is not without its challenges.

demonstrated the feasibility of incorporating this system with multiple

Accessing the left atrium through the interatrial septum with a large

different transcatheter valves. Future studies in a broader representa-

device can lead to unexpected movements into either the left atrium

tion of patients are warranted.

or ventricle which may cause injury. As compared with TAVR, delivery
devices for TMVR are larger profile which can limit maneuverability
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within the left atrium. Steerable guiding catheters may help to par-
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Edwards Lifesciences. Dr Wang is a consultant for Edwards
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